Debate: When should we intervene in unstable angina?

Current Controlled Trials in Cardiovascular Medicine

Volumn 1, Issue 1, 2000, Pages 15-18

  Laskey, W K ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Acute coronary syndromes; Early intervention; Percutaneous coronary intervention

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; EARLY DIAGNOSIS; HAZARD; HUMAN; ISCHEMIC HEART DISEASE; NOTE; RISK; RISK BENEFIT ANALYSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0034466634     PISSN: 14686708     EISSN: None     Source Type: Journal    
DOI: 10.1186/CVM-1-1-015     Document Type: Note

References (30)

1. Clinical Practice Guideline No. 10. Unstable angina: Diagnosis and management
2. Unstable angina: Good long-term outcome after a complicated early course
3. Protective effects of aspirin against myocardial infarction and death in men with unstable angina
4. Aspirin, heparin or both to treat acute unstable angina
5. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicenter study
6. Outcomes at 1 year after an invasive compared with a non-invasive strategy in unstable coronary artery disease: The FRISC II invasive randomized trial
7. One year results of the TIMI IIIB clinical trial: A randomized comparison of tissue-type plasminogen activator vs. Placebo and early invasive vs. Conservative strategies in unstable angina and non-Q wave myocardial infarction
8. Variables predictive of successful medical therapy in patients with unstable angina
9. Percutaneous transluminal coronary angioplasty for unstable angina
10. Atherosclerosis - An inflammatory disease
11. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metelloproteinases and implications for plaque rupture
12. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
13. Acute coronary syndromes - Unstable angina and non-Q wave myocardial infarction
14. Inflammation, the endothelium and the acute coronary syndromes
15. The prognostic value of C-reactive protein and serum amyloid - A protein in severe unstable angina
16. C-Reactive protein is a potent predictor of mortality independent of and in combination with troponin T in acute coronary syndromes: A TIMI 11A sub-study
17. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
18. Inhibition of pro-inflammatory cytokine production by pravastatin
19. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris
20. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty
21. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina
22. Large, sustained cardiac lipid peroxidation and reduced antioxidant capacity in the coronary circulation after brief episodes of myocardial ischemia
23. Acute coronary syndromes: Biology
24. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary intervention
25. Myonecrosis after revascularization procedures
26. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
27. Outcomes in patients with acute non-Q-wave myocardial infarction randomly asigned to an invasive as compared with a conservative management approach
28. Randomized, placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
29. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
30. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction